Search

Background: Lung cancer is a major cause of death in New Zealand. In recent years, targeted therapies have improved outcomes. Aim: To determine the uptake of anaplastic lymphoma kinase (ALK) testing, and the prevalence, demographic profile and outcomes of ALK‐positive non‐small‐cell lung cancer (NSCLC), in New Zealand, where no national ALK‐testing guidelines or subsidised ALK tyrosine kinase inhibitor (TKI) therapies are available. Methods: A population‐based observational study reviewed databases to identify patients presenting with non‐squamous NSCLC over 6.5 years in northern New Zealand. We report the proportion tested for ALK gene rearrangements and the results. NSCLC samples tested by fluorescence in situ hybridisation were retested by next generation sequencing and ALK immunohistochemistry. A survival analysis compared ALK‐positive patients treated or not treated with ALK TKI therapy. Results: From a total of 3130 patients diagnosed with non‐squamous NSCLC, 407 (13%) were tested for ALK gene rearrangements, and patient selection was variable and inequitable. Among those tested, 34 (8.4%) had ALK‐positive NSCLC. ALK‐positive disease was more prevalent in younger versus older patients, non‐smokers versus smokers and in Māori, Pacific or Asian ethnic groups than in New Zealand Europeans. Fluorescence in situ hybridisation, ALK immunohistochemistry and next generation sequencing showed broad concordance for detecting ALK–positive disease under local testing conditions. Among patients with ALK‐positive metastatic NSCLC, those treated with ALK TKI survived markedly longer than those not treated with ALK TKI (median overall survival 5.12 vs 0.55 years). Conclusion: Lung cancer outcomes in New Zealand may be improved by providing national guidelines and funding policy for ALK testing and access to subsidised ALK TKI therapy. [ABSTRACT FROM AUTHOR]

• Rapid chemical profiling of Manuka honey with ambient mass spectrometry and chemometric modelling. • Real-time authentication of Manuka honey by production batch. • Chemometric differentiation of Manuka honey by production batch, brand, and adulteration scenarios. • Honey authentication and fraud detection of Manuka honey for brand protection. Manuka honey is a high-value and commonly adulterated food commodity that is produced by Apis mellifera bees from the nectar of the bush Leptospermum scoparium found exclusively in New Zealand and some parts of Australia. In this study, a rapid method using a compact atmospheric solid analysis probe (ASAP) mass spectrometer (MS) and chemometric modelling was used for the authentication of Manuka honey. Class separation was observed for Manuka honey of different production batches, brands, and grades, whereas no class separation was observed for Manuka honey of the same production batch. A one-class model training set of a production batch of honey was built (R2 = 0.845; Q2 = 0.686). Model validation with a prediction set of Manuka honey consisting of samples of the same production batch not used in the model, different production batches, brands, and grades gave and a perfect classifier (AUC = 1) for the receiver operator characteristic (ROC) indicating 100 % correct classification of class samples and outliers. Additionally, validation of the model against adulterated Manuka honey gave an AUC = 0.96 for the ROC. The results in this study indicate that compositional differences between production batches of Manuka honey could be used as unique chemical fingerprints for Manuka honey authentication for the purpose of brand protection and fraud detection. [ABSTRACT FROM AUTHOR]